HomeComparePHRRF vs GBDC

PHRRF vs GBDC: Dividend Comparison 2026

PHRRF yields 4155.41% · GBDC yields 11.85%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PHRRF wins by $10365691035258.20M in total portfolio value
10 years
PHRRF
PHRRF
● Live price
4155.41%
Share price
$0.05
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$10365691035278.97M
Annual income
$9,897,164,253,693,497,000.00
Full PHRRF calculator →
GBDC
GBDC
● Live price
11.85%
Share price
$12.66
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.78M
Annual income
$16,389,263.41
Full GBDC calculator →

Portfolio growth — PHRRF vs GBDC

📍 PHRRF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPHRRFGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PHRRF + GBDC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PHRRF pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PHRRF
Annual income on $10K today (after 15% tax)
$353,210.06/yr
After 10yr DRIP, annual income (after tax)
$8,412,589,615,639,472,000.00/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.11/yr
After 10yr DRIP, annual income (after tax)
$13,930,873.90/yr
At 15% tax rate, PHRRF beats the other by $8,412,589,615,625,542,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PHRRF + GBDC for your $10,000?

PHRRF: 50%GBDC: 50%
100% GBDC50/50100% PHRRF
Portfolio after 10yr
$5182845517649.87M
Annual income
$4,948,582,126,854,944,000.00/yr
Blended yield
95.48%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

PHRRF
No analyst data
Altman Z
-14.2
Piotroski
1/9
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.6% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PHRRF buys
0
GBDC buys
0
No recent congressional trades found for PHRRF or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPHRRFGBDC
Forward yield4155.41%11.85%
Annual dividend / share$2.00$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1%
Portfolio after 10y$10365691035278.97M$20.78M
Annual income after 10y$9,897,164,253,693,497,000.00$16,389,263.41
Total dividends collected$10333779416010.36M$20.36M
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: PHRRF vs GBDC ($10,000, DRIP)

YearPHRRF PortfolioPHRRF Income/yrGBDC PortfolioGBDC Income/yrGap
1← crossover$426,241$415,541.24$12,490$1,790.28+$413.8KPHRRF
2$17,009,425$16,553,347.24$16,522$3,157.73+$16.99MPHRRF
3$635,556,863$617,356,778.09$23,578$5,898.68+$635.53MPHRRF
4$22,238,480,006$21,558,434,161.98$37,115$11,886.75+$22238.44MPHRRF
5$728,787,067,208$704,991,893,601.52$66,136$26,423.57+$728787.00MPHRRF
6$22,371,952,866,480$21,592,150,704,567.71$137,257$66,491.44+$22371952.73MPHRRF
7$643,400,978,312,961$619,462,988,745,827.60$341,734$194,868.54+$643400977.97MPHRRF
8$17,338,253,847,239,070$16,649,814,800,444,200.00$1,050,788$685,133.02+$17338253846.19MPHRRF
9$437,875,496,808,855,800$419,323,565,192,309,950.00$4,099,314$2,974,971.01+$437875496804.76MPHRRF
10$10,365,691,035,278,973,000$9,897,164,253,693,497,000.00$20,775,530$16,389,263.41+$10365691035258.20MPHRRF

PHRRF vs GBDC: Complete Analysis 2026

PHRRFStock

PharmaTher Holdings Ltd., a clinical-stage psychedelics biotech company, focuses on the research, development, and commercialization of novel uses, formulations, and delivery methods of psychedelics to treat mental illness, neurological, and pain disorders. The company's product in pipeline includes Ketamine intravenous injection, which is in Phase II and III clinical trials for Parkinson's disease, anesthesia and sedation, and amyotrophic lateral sclerosis indications. Its pipeline also comprises Ketamine Patch that is in Phase I and II clinical trials for treating depression, mental health, complex regional pain syndrome, and pain disorders; and Ketamine Pump, which is in Phase II clinical trial to treat metal health, pain disorders, and surgery/procedure. In addition, the company engages in the development of PHARMAPATCH, a microneedle patch to deliver psychedelics. It has collaboration agreements with LTS Lohmann Therapie-Systeme AG for developing Ketamin microneedle patch; Alcami Corporation to develop Ketamin injectables/infusions; BioRAE, Inc. for the development of Ketamin pumps; Revive Therapeutics Ltd. to develop psilocybin microneedle patch; Gesval S.A. for the development of patented continuous-flow process technology for the preparation of ketamine and ketamine analogs; and PharmaTher's to create a proprietary wearable ketamine delivery solution for mental health, neurological and pain disorders. The company was incorporated in 2019 and is headquartered in Toronto, Canada.

Full PHRRF Calculator →

GBDCBDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this PHRRF vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PHRRF vs SCHDPHRRF vs JEPIPHRRF vs OPHRRF vs KOPHRRF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.